上海现代制药股份有限公司 非金融企业债务融资工具信息披露事务管理制度 （2025 年 10 月 29 日经八届二十五次董事会审议修订） 第一章 总则 第一条 为规范上海现代制药股份有限公司（以下简称公司）在银行间债券 市场发行非金融企业债务融资工具（以下简称债务融资工具）的信息披露行为， 加强公司信息披露事务管理，保护投资者合法权益，促进公司依法规范运作，根 据《中华人民共和国公司法》《公司信用类债券信息披露管理办法》《银行间债券 市场非金融企业债务融资工具管理办法》及《银行间债券市场非金融企业债务融 资工具信息披露规则》等相关法律法规，结合公司章程有关规定和公司实际情况， 制定本制度。 第二条 债务融资工具发行及存续期的信息披露适用本制度。法律法规或中 国银行间市场交易商协会（以下简称交易商协会）另有规定的，从其规定。 本制度所称存续期为债务融资工具发行登记完成直至付息兑付全部完成或 发生债务融资工具债权债务关系终止的其他情形期间。 第三条 本制度适用于公司及其所属子公司。 第二章 基本原则和一般规定 第四条 信息披露是公司的持续性责任，公司应当根据《中华人民共和国公 司法》《公司信用类债券信息披露管理办法 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥2,042,719,648.45, a decrease of 22.43% year-on-year[5] - The total profit for the period was ¥190,562,105.19, down 48.54% compared to the same quarter last year[5] - Net profit attributable to shareholders was ¥129,104,688.63, reflecting a decline of 45.31% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥102,282,542.35, a significant drop of 58.01% compared to the previous year[5] - The basic and diluted earnings per share were both ¥0.0963, down 45.28% year-on-year[5] - Total operating revenue for the first three quarters of 2025 was CNY 6.92 billion, a decrease of 19.5% compared to CNY 8.59 billion in the same period of 2024[20] - Net profit for the first three quarters of 2025 was CNY 933.23 million, a decline of 22.2% from CNY 1.20 billion in 2024[21] - Operating profit for the first three quarters of 2025 was CNY 1.10 billion, down 25.0% from CNY 1.47 billion in the previous year[21] - Basic earnings per share for the first three quarters of 2025 were CNY 0.5974, down from CNY 0.7117 in 2024[22] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥19,330,801,003.68, a decrease of 3.13% from the end of the previous year[6] - The company's current assets totaled RMB 10,799,627,521.67, down from RMB 11,684,104,124.22, indicating a decrease of about 7.53%[16] - Total liabilities decreased to RMB 3,632,219,485.35 from RMB 4,633,633,097.68, a reduction of about 21.59%[17] - The company's equity attributable to shareholders increased to RMB 13,638,317,886.42 from RMB 13,203,924,172.51, an increase of approximately 3.29%[18] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥1,141,629,735.11, down 43.66% year-on-year[5] - Cash flow from operating activities generated CNY 1.14 billion, a decrease of 43.7% compared to CNY 2.03 billion in 2024[25] - The net cash flow from investment activities was negative at CNY 1.67 billion, worsening from a negative CNY 1.35 billion in 2024[25] - In the first three quarters of 2025, the net cash flow from financing activities was -$1.64 billion, compared to -$407.06 million in the same period of 2024[26] - The total cash outflow from financing activities in the first three quarters of 2025 was $1.64 billion, significantly higher than $457.06 million in 2024[26] Expenses - Total operating costs decreased to CNY 5.86 billion, down 18.0% from CNY 7.15 billion year-over-year[20] - Research and development expenses for the first three quarters of 2025 were CNY 331.63 million, a reduction of 20.3% from CNY 416.21 million in 2024[20] - Sales expenses significantly decreased to CNY 354.82 million, down 63.4% from CNY 969.12 million year-over-year[20] Market Factors - The decline in profits was attributed to industry cycles, market competition, and reduced demand for key products[9] - The company reported a significant increase in non-recurring gains and losses, impacting the net profit figures[10] Cash and Equivalents - Cash and cash equivalents decreased to RMB 4,141,241,012.60 from RMB 6,211,941,467.03, representing a decline of approximately 33.39%[15] - The cash and cash equivalents at the end of Q3 2025 were $3.99 billion, down from $5.42 billion at the end of Q3 2024[26] - The net increase in cash and cash equivalents for the first three quarters of 2025 was -$2.16 billion, while it was $289.39 million in the same period of 2024[26] - The impact of exchange rate changes on cash and cash equivalents was $18.64 million in 2025, compared to $24.55 million in 2024[26]

国药现代公告，第三季度营收为20.43亿元，下降22.43%；净利润为1.29亿元，下降45.31%。前三季度 营收为69.2亿元，下降19.47%；净利润为8.01亿元，下降16.07%。 ...

证券代码：600420 证券简称：国药现代 公告编号：2025-082 上海现代制药股份有限公司 关于拟中选第十一批全国药品集中采购的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025年10月27日，上海现代制药股份有限公司（以下简称公司）及部分下属 子公司参加了国家组织药品联合采购办公室（以下简称联合采购办公室）组织的 第十一批全国药品集中采购工作，部分药品拟中选本次集中采购。现将相关情况 公告如下： 一、拟中选情况 （一）拟中选产品基本情况 采购周期内若提前完成当年约定采购量，超出部分中选企业仍应按中选价进 行供应，直至采购周期届满。 2、本次拟中选结果尚需在"上海阳光医药采购网"公示，并接受申投诉， 上述品种的拟中选情况以联合采购办公室发布的最终公告信息为准。 | 公司名 | 药品名 | | | | 适应症 | 拟主供地 代表规格 拟中选价格 | | --- | --- | --- | --- | --- | --- | --- | | 称 | 称 | | | | | 区 | | | | | | | 适用于饮 ...

格隆汇10月28日丨国药现代(600420.SH)公布，2025年10月27日，公司及部分下属子公司参加了国家组 织药品联合采购办公室（简称联合采购办公室）组织的第十一批全国药品集中采购工作，部分药品拟中 选本次集中采购。 ...

Core Viewpoint - The company, Guoyao Modern, announced participation in the 11th national centralized procurement organized by the National Organization for Drug Procurement Office, with six out of seven products expected to be selected for procurement, impacting the company's revenue for 2024 [1] Group 1: Procurement Participation - Guoyao Modern and its subsidiaries participated in the 11th batch of national drug centralized procurement [1] - A total of seven products from the company were eligible for this procurement, with six products expected to be selected [1] Group 2: Financial Impact - The total expected sales revenue from the selected products for 2024 is approximately 29,100.71 thousand yuan, accounting for about 2.66% of the company's projected revenue for the year [1] - The product not selected, sodium bicarbonate injection, is projected to have a sales revenue of 743.63 thousand yuan for 2024, representing a low proportion of the overall revenue [1]

Core Viewpoint - Shanghai Modern Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., has received approval for its product, Lincomycin Hydrochloride Injection, to pass the consistency evaluation for generic drugs, which is expected to enhance market expansion and sales potential for the product [1][3]. Group 1: Drug Information - The drug Lincomycin Hydrochloride Injection is an antibiotic used for treating severe infections caused by sensitive strains of bacteria such as Streptococcus, Pneumococcus, and Staphylococcus [2]. - The product's sales in public medical institutions in China are projected to be approximately RMB 77.29 million in 2024 [2]. - The cumulative R&D investment for the consistency evaluation of Lincomycin Hydrochloride Injection by China National Pharmaceutical Group Rongsheng is about RMB 3.61 million (unaudited) [2]. Group 2: Company Impact - The approval of Lincomycin Hydrochloride Injection for consistency evaluation is anticipated to positively influence the product's future market expansion and sales [3]. - The current operational performance of the company is not expected to be significantly impacted by this development [3].

证券代码：600420 证券简称：国药现代 公告编号：2025-081 二、药品研发及市场情况 盐酸林可霉素注射液为系统用抗感染药，作用于敏感菌核糖体的 50S 亚基， 阻止肽链的延长，从而抑制细菌细胞的蛋白质合成，临床主要适用于治疗由链球 菌、肺炎球菌和葡萄球菌等敏感菌株引起的严重感染。 米内网数据库显示，盐酸林可霉素注射液 2024 年全国公立医疗机构销售额 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，上海现代制药股份有限公司（以下简称公司）全资子公司国药集团容 生制药有限公司（以下简称国药容生）收到国家药品监督管理局核准签发的《药 品补充申请批准通知书》，批准盐酸林可霉素注射液通过仿制药质量和疗效一致 性评价（以下简称一致性评价）。现将相关情况公告如下： 一、药品基本信息 药品名称：盐酸林可霉素注射液 通知书编号：2025B04898 剂型：注射剂 规格：2ml:0.6g（按 C₁₈H₃₄N₂O₆S 计） 注册分类：化学药品 原药品批准文号：国药准字 H41020041 药品生产企业：国药集团容生制药有限公司 ...

Core Viewpoint - The company, China National Pharmaceutical Group Modern (600420.SH), announced that its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the supplemental application of Famotidine injection, which has passed the consistency evaluation of generic drug quality and efficacy [1]. Group 1 - The approval allows Famotidine injection to be used for treating upper gastrointestinal bleeding caused by various reasons, excluding tumors and esophageal or gastric variceal bleeding [1]. - Famotidine is classified as a histamine H2 receptor antagonist and is primarily used for conditions related to mucosal erosion in the stomach and duodenum [1].

Core Viewpoint - The company Guoyao Modern (600420.SH) announced that its wholly-owned subsidiary, Guoyao Group Rongsheng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the supplementary application of Famotidine injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - Guoyao Modern's subsidiary has been granted a supplementary application approval for Famotidine injection [1] - Famotidine is an H2 receptor antagonist used for treating upper gastrointestinal bleeding caused by various factors, excluding tumors and esophageal or gastric varices [1] - The approval indicates the company's capability to produce a drug that meets regulatory standards for quality and efficacy [1]